Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call
February 25 2014 - 7:30AM
Business Wire
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that the Company expects to report fourth quarter
and full year 2013 financial results after the market closes
Wednesday, March 12, 2014. CEO, Jack Khattar, and CFO, Greg
Patrick, will be hosting a conference call on Thursday, March 13,
2014 at 9:00 AM Eastern Time, to discuss 2013 financial results and
to provide a business update.
A live webcast will be available at www.supernus.com. Following
the live call, a replay will be available on the Company's website
under ’Investor Info’. The webcast will be archived on the
Company's website for 30 business days following the live call.
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
Conference dial-in: 877-288-1043 International
dial-in: 970-315-0267 Conference ID: 54977145
Conference Call Name:
Supernus Pharmaceuticals 4Q 2013 Earnings
Conference Call
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR™ (extended-release
topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in
ADHD, including ADHD patients with impulsive aggression. These
product candidates include SPN-810 for impulsive aggression in ADHD
and SPN-812 for ADHD.
Supernus Pharmaceuticals, Inc.Jack A. Khattar,
301-838-2591President and CEOorGregory S. Patrick, 301-838-2591Vice
President and CFOorInvestor Contact:Cockrell Group,
877-889-1972investorrelations@thecockrellgroup.comcockrellgroup.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024